Aurinia Pharmaceuticals Inc $AUPH Shares Sold by Swiss National Bank

Swiss National Bank decreased its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 1.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 235,800 shares of the biotechnology company’s stock after selling 3,200 shares during the quarter. Swiss National Bank owned 0.17% of Aurinia Pharmaceuticals worth $1,896,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in AUPH. GF Fund Management CO. LTD. acquired a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at approximately $27,000. Tower Research Capital LLC TRC raised its holdings in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at approximately $31,000. GAMMA Investing LLC raised its holdings in Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 1,744 shares in the last quarter. Finally, Natixis acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth approximately $49,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH opened at $12.27 on Friday. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The firm has a market cap of $1.62 billion, a PE ratio of 28.54 and a beta of 1.23. The company’s 50 day simple moving average is $9.48 and its 200-day simple moving average is $8.53. Aurinia Pharmaceuticals Inc has a 12-month low of $6.42 and a 12-month high of $12.53.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million for the quarter, compared to analysts’ expectations of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

Wall Street Analysts Forecast Growth

AUPH has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Royal Bank Of Canada boosted their price objective on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, Aurinia Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $12.00.

Insider Activity

In other Aurinia Pharmaceuticals news, Director Kevin Tang bought 1,000,000 shares of the stock in a transaction dated Friday, August 1st. The shares were acquired at an average cost of $10.12 per share, for a total transaction of $10,120,000.00. Following the completion of the transaction, the director owned 11,029,500 shares in the company, valued at approximately $111,618,540. The trade was a 9.97% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have purchased 1,300,000 shares of company stock worth $13,590,000 in the last 90 days. Company insiders own 12.20% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.